Welcome To 3rd NASH Summit Europe

Returning as the only NASH forum exclusively facilitating industry-to-industry dialogue and collaboration in Europe; the 3rd Annual NASH Summit Europe will once again showcase leading data and leverage expert insights to advance pipeline success in NASH.

Across 3 days, the NASH biopharmaceutical community will converge at this unique summit to analyse progression and opportunity through a tighter lens and overcome fundamental challenges in NASH drug development. Be part of the ground-breaking discussion of topics including:

  • The rationale and mechanisms of action of stand-alone versus combination therapeutics
  • What we know about the pricing and reimbursement landscape for successful candidates
  • Adhering to regulatory guidelines and overcoming clinical challenges including an understanding of the patient perspective
  • The mechanism of action and preclinical efficacy of emerging candidates
  • Addressing the involvement of genetics in driving NASH pathophysiology and heterogeneity

As competition in the NASH space increases, find out how you can move your candidate into differentiation and identify the best mode of action to stay ahead as this field looks to overcome its current limitations.

So whether you’re part of a NASH-focused biotech, a pharmaceutical organization assessing this exciting field, or an academic researcher with breakthrough findings, join the NASH Summit as we explore the global advances in translational research, and meet like-minded peers who are continuing to understand the causal and therapeutic potential of the NASH therpeutics.

3 Streams Of Granular Scientific Content




Learn how leaders in the field are defining host microbiome interactions,
identifying new targets and addressing the current challenges in the pre-clinical
development of microbiome-based
therapeutics across a broad range of modalities and disease phenotypes.

Navigate through the evolving
translational, clinical, regulatory
and manufacturing challenges of
microbiome-based therapeutics to
help improve clinical outcomes
and bring these products to a
commercial scale.

Review research on the identification
of microbiome-derived biomarkers and
better understand their application to
help guide clinical development, and
as a patient stratification tool for predetermining therapeutic response across multiple disease phenotypes.

Hear What Our Customers Say

"As a newcomer to the microbiome field, this conference provided an excellent overview.”

Richard Shanksky
Seres  Therapeutics

“It was a great conference to effectively learn the current trends in microbiome drug development around the world.”

Nanae Izumi
Daiichi Sankyo